NCT00909233

Brief Summary

This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction (ED) who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,221

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2007

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

May 8, 2009

Completed
19 days until next milestone

First Posted

Study publicly available on registry

May 27, 2009

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2010

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

December 15, 2014

Status Verified

December 1, 2014

Enrollment Period

2.6 years

First QC Date

May 8, 2009

Last Update Submit

December 12, 2014

Conditions

Keywords

Erectile dysfunction,Phosphodiesterase Inhibitors

Outcome Measures

Primary Outcomes (1)

  • Efficacy of patients with LEVITRA treatment

    After 6 months

Secondary Outcomes (5)

  • LEVITRA treatment improved the patient's erection

    After 6 months

  • LEVITRA improved the patient's erection after Minimum and Maximum Intervals between LEVITRA intake and the start of intercourse

    After 6 months

  • Reporting a second successful intercourse within 24 hours of dosing

    After 6 months

  • Patients prefer LEVITRA over last Erectile Dysfunction treatment

    After 6 months

  • Tolerability of patients with LEVITRA treatment

    After 6 months

Study Arms (1)

Group 1

Drug: Vardenafil, (Levitra, BAY38-9456)

Interventions

Patients under daily life treatment receiving Levitra according to local drug information.

Group 1

Eligibility Criteria

Age18 Years - 64 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Primary care clinic

You may qualify if:

  • This investigation targets either the patients of 18 years-old or older and under 65 years-old with organic or mixed erectile dysfunction who cannot obtain sufficient efficacy by dose 10mg of Levitra, and the target patients dose is increased to Levitra 20mg. This investigation will be limited to the patients whose tolerability of Levitra 10mg is judged to be no problem.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Many Locations, Japan

Location

MeSH Terms

Conditions

Erectile Dysfunction

Interventions

Vardenafil Dihydrochloride

Condition Hierarchy (Ancestors)

Genital Diseases, MaleGenital DiseasesUrogenital DiseasesSexual Dysfunction, PhysiologicalMale Urogenital DiseasesSexual Dysfunctions, PsychologicalMental Disorders

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPiperazines

Study Officials

  • Bayer Study Director

    Bayer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 8, 2009

First Posted

May 27, 2009

Study Start

August 1, 2007

Primary Completion

March 1, 2010

Study Completion

December 1, 2011

Last Updated

December 15, 2014

Record last verified: 2014-12

Locations